本次获批将进一步拓展联邦制药眼科产品布局，强化公司于眼科抗感染治疗领域的优势地位。公司将持 续致力于推进新产品研发，为临床提供全面、优质的用药解决方案，预期将为公司及其股东创造更大收 益。 盐酸莫西沙星属于第四代喹诺酮类药物，具有广谱的抗菌活性。盐酸莫西沙星滴眼液适用于治疗金黄色 葡萄球菌、流感嗜血杆菌、沙眼衣原体等敏感微生物引起的细菌性结膜炎。该产品不含防腐剂，避免了 抑菌剂对眼组织的毒性作用，适用人群广泛。现时，盐酸莫西沙星滴眼液为国家医保目录(2024年版)乙 类药品。 格隆汇12月9日丨联邦制药(03933.HK)公告，公司全资附属公司珠海联邦制药股份有限公司中山分公司 申报的盐酸莫西沙星滴眼液(规格：0.5%(3ml:15mg)、0.5%(5ml:25mg))通过中国国家药品监督管理局上 市审批，药品批准文号分别为：国药准字H20256128、国药准字H20256129。 ...

Core Viewpoint - Kweichow Moutai has received a notice of acceptance for the registration application of Duzhuaiyin capsules from the National Medical Products Administration, indicating progress in the approval process for a new product aimed at treating osteoarthritis in hip and knee joints [1] Group 1 - The product is classified as a chemical drug of category 4 and is in capsule form, targeting osteoarthritis treatment [1] - The company plans to actively promote the product's licensing work and will continue to monitor the approval status [1]